3 active not recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Bepirovirsen: new trials by email Literature Review of Bepirovirsen trials Research Report on Bepirovirsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bepirovirsen Liver Biopsy Study Bepirovirsen, Liver biopsy, Optional Liver biopsy - HEPATITIS B CHRONIC, Hepatitis B Chronic Infection | Phase 2 | Not yet recruiting | National University Health System, Singapore | 30 | 2026-07-01 | 2026-07-10 |
| A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen - Chronic Hepatitis B Virus Infection, Hepatitis B | Phase 2 | Active not recruiting | GlaxoSmithKline | 283 | 2024-11-11 | 2026-07-07 |
| Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) Bepirovirsen, Placebo - Hepatitis B | Phase 2 | Active not recruiting | GlaxoSmithKline | 153 | 2024-09-17 | 2026-07-08 |
| Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection GSK3965193, Placebo to match GSK3965193, Bepirovirsen - Hepatitis B | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 74 | 2022-04-14 | 2026-10-14 |
| A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy GSK3228836, GSK3528869A, Control - Hepatitis B, Chronic | Phase 2 | Completed | GlaxoSmithKline | 174 | 2022-03-22 | 2025-12-30 |
| Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) Bepirovirsen, Placebo - Hepatitis B | Phase 2 | Active not recruiting | GlaxoSmithKline | 360 | 2021-12-14 | 2026-06-24 |
Hepatitis B (6) · Hepatitis B, Chronic (4) · Acquired Immunodeficiency Syndrome (1)
GlaxoSmithKline (5) · National University Health System, Singapore (1)
France (5) · Italy (5) · United Kingdom (5) · Canada (4) · Singapore (4) · Spain (4) · Taiwan (4) · Brazil (3) · Germany (3) · Hong Kong (3) · South Africa (3) · South Korea (3) · Thailand (3) · United States (3) · Argentina (2)
Seng Gee Prof Lim, Professor (1)
2023 (3)